An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Vick, Binje ^a,b   Rothenberg, Maja ^c   Sandhöfer, Nadine ^a,b,c   Carlet, Michela ^a   Finkenzeller, Cornelia ^a   Krupka, Christina ^a,c   Grunert, Michaela ^a   Trumpp, Andreas ^b,d   Corbacioglu, Selim ^e   Ebinger, Martin ^b,f   André, Maya C ^f,g   Hiddemann, Wolfgang ^a,b,c   Schneider, Stephanie ^c   Subklewe, Marion ^a,b,c   Metzeler, Klaus H ^a,c   Spiekermann, Karsten ^a,b,c   Jeremias, Irmela ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d Hi STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine GmbH   (Germany)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE IMAGING; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOLECULAR IMAGING; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PRIMARY TUMOR; TRANSGENE; ACUTE MYELOID LEUKEMIA; ANIMAL; CANCER STEM CELL; DISEASE MODEL; DRUG SCREENING; GENETIC ENGINEERING; GENETICS; LUMINESCENCE; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; THREE DIMENSIONAL IMAGING;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; IMAGING, THREE-DIMENSIONAL; LEUKEMIA, MYELOID, ACUTE; LUMINESCENT MEASUREMENTS; MICE; MUTATION; NEOPLASTIC STEM CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84961291118     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0120925     Document Type: Article

References (60)

1. Guzman ML, Allan JN. Leukemia stem cells in personalized medicine. Stem Cells. 2014; 32(4):844-51 doi: 10.1002/stem.1597 PMID: 24214290
2. Shoemaker RH, Monks A, Alley MC, Scudiero DA, Fine DL, et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res. 1988; 276: 265-286. PMID: 3051021
3. Pan C, Kumar C, Bohl S, Klingmueller U, Mann M. Comparative proteomic phenotyping of cell lines and primary cells to assess preservation of cell type-specific functions. Mol Cell Proteomics. 2009; 8: 443-450. doi: 10.1074/mcp.M800258-MCP200 PMID: 18952599
4. Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330. Blood. 2014; 123: 356-365. doi: 10.1182/blood-2013-08-523548 PMID: 24300852
5. Cesano A, Hoxie JA, Lange B, Nowell PC, Bishop J, et al. The severe combined immunodeficient (SCID) mouse as a model for human myeloid leukemias. Oncogene. 1992; 7: 827-836. PMID: 1570153
6. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-648. PMID: 7509044
7. Sawyers CL, Gishizky ML, Quan S, Golde DW, Witte ON. Propagation of human blastic myeloid leukemias in the SCID mouse. Blood. 1992; 79: 2089-2098. PMID: 1562735
8. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997; 3: 730-737. PMID: 9212098
9. Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol. 2004; 5: 738-743. PMID: 15170211
10. Lumkul R, Gorin NC, Malehorn MT, Hoehn GT, Zheng R, et al. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia. 2002; 16: 1818-1826. PMID: 12200698
11. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood. 2006; 107: 1166-1173. PMID: 16234360
12. Rombouts WJ, Martens AC, Ploemacher RE. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model. Leukemia. 2000; 14: 889-897. PMID: 10803522
13. Agliano A, Martin-Padura I, Mancuso P, Marighetti P, Rabascio C, et al. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. Int J Cancer. 2008; 123: 2222-2227. doi: 10.1002/ijc.23772 PMID: 18688847
14. Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 2005; 106: 1565-1573. PMID: 15920010
15. Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25: 1315-1321. PMID: 17952057
16. Malaise M, Neumeier M, Botteron C, Dohner K, Reinhardt D, et al. Stable and reproducible engraftment of primary adult and pediatric acute myeloid leukemia in NSG mice. Leukemia. 2011; 25: 1635-1639. doi: 10.1038/leu.2011.121 PMID: 21647161
17. Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, et al. A robust xeno-transplantation model for acute myeloid leukemia. Leukemia. 2009; 23: 2109-2117. doi: 10.1038/leu.2009.143 PMID: 19626050.
18. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, et al. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005; 174: 6477-6489. PMID: 15879151
19. Woiterski J, Ebinger M, Witte KE, Goecke B, Heininger V, et al. Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcgammanull mice reflects individual leukemogenecity and highly correlates with clinical outcome. Int J Cancer. 2013; 133: 1547-1556. doi: 10.1002/ijc.28170 PMID: 23526331
20. Dick JE. Acute myeloid leukemia stem cells. Ann N Y Acad Sci. 2005; 1044: 1-5. PMID: 17099945
21. Dick JE. Stem cell concepts renew cancer research. Blood. 2008; 112: 4793-4807. doi: 10.1182/blood-2008-08-077941 PMID: 19064739
22. Vascotto C, Lirussi L, Poletto M, Tiribelli M, Damiani D, et al. Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology. Oncogene. 2014; 33: 2876-87 doi: 10.1038/onc.2013.251 PMID: 23831574
23. Ye P, Zhao L, McGirr C, Gonda TJ. MYB down-regulation enhances sensitivity of U937 myeloid leukemia cells to the histone deacetylase inhibitor LBH589 in vitro and in vivo. Cancer Lett. 2014; 343: 98-106. doi: 10.1016/j.canlet.2013.09.022 PMID: 24075958
24. Zimmerman EI, Turner DC, Buaboonnam J, Hu S, Orwick S, et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood. 2013; 122: 3607-3615. doi: 10.1182/blood-2013-07-513044 PMID: 24046014
25. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138: 286-299.doi: 10.1016/j.cell.2009.05.045 PMID: 19632179
26. Wunderlich M, Mizukawa B, Chou FS, Sexton C, Shrestha M, et al. AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model. Blood. 2013; 121: e90-7. doi: 10.1182/blood-2012-10-464677 PMID: 23349390
27. Saito Y, Uchida N, Tanaka S, Suzuki N, Tomizawa-Murasawa M, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 2010; 28: 275-280. doi: 10.1038/nbt.1607 PMID: 20160717
28. Barrett DM, Seif AE, Carpenito C, Teachey DT, Fish JD, et al. Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood. 2011; 118: e112-7. doi: 10.1182/blood-2011-04-346528 PMID: 21856863
29. Bomken S, Buechler L, Rehe K, Ponthan F, Elder A, et al. Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia. 2013; 27: 718-721. doi: 10.1038/leu.2012.206 PMID: 22858908
30. Duy C, Hurtz C, Shojaee S, Cerchietti L, Geng H, et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011; 473: 384-388. doi: 10.1038/nature09883 PMID: 21593872
31. Terziyska N, Castro Alves C, Groiss V, Schneider K, Farkasova K, et al. In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice. PLoS One. 2012; 7: e52798. doi: 10.1371/journal.pone.0052798 PMID: 23300782
32. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25: 1754-1760. doi: 10.1093/bioinformatics/btp324 PMID: 19451168
33. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 2012; 22: 568-576. doi: 10.1101/gr.129684.111 PMID: 22300766
34. Ye K, Schulz MH, Long Q, Apweiler R, Ning Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics. 2009; 25: 2865-2871. doi: 10.1093/bioinformatics/btp394 PMID: 19561018
35. von Bonin M, Wermke M, Cosgun KN, Thiede C, Bornhauser M, et al. In vivo expansion of co-transplanted T cells impacts on tumor re-initiating activity of human acute myeloid leukemia in NSG mice. PLoS One. 2013; 8: e60680. doi: 10.1371/journal.pone.0060680 PMID: 23585844
36. Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, et al. A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia. Blood. 2012; 119: 3571-3577. doi: 10.1182/blood-2011-06-364182 PMID: 22262762
37. Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Invest. 2011; 121: 384-395. doi: 10.1172/JCI41495 PMID: 21157036
38. Taussig DC, Miraki-Moud F, Anjos-Afonso F, Pearce DJ, Allen K, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008; 112: 568-575. doi: 10.1182/blood-2007-10-118331 PMID: 18523148
39. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089. doi: 10.1056/NEJMoa1112304 PMID: 22417203
40. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481: 506-510. doi: 10.1038/nature10738 PMID: 22237025
41. Klco JM, Spencer DH, Miller CA, Griffith M, Lamprecht TL, et al. Functional Heterogeneity of Genetically Defined Subclones in Acute Myeloid Leukemia. Cancer Cell. 2014; 25: 379-92. doi: 10.1016/j.ccr.2014.01.031 PMID: 24613412
42. Harismendy O, Schwab RB, Bao L, Olson J, Rozenzhak S, et al. Detection of low prevalence somatic mutations in solid tumors with ultra-deep targeted sequencing. Genome Biol. 2011; 12: R124. doi: 10.1186/gb-2011-12-12-r124 PMID: 22185227
43. Modlich U, Navarro S, Zychlinski D, Maetzig T, Knoess S, et al. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther. 2009; 17: 1919-1928. doi: 10.1038/mt.2009.179 PMID: 19672245
44. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, et al. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia. 1999; 1: 303-310. PMID: 10935484
45. Rabinovich BA, Ye Y, Etto T, Chen JQ, Levitsky HI, et al. Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer. Proc Natl Acad Sci U S A. 2008; 105: 14342-14346. doi: 10.1073/pnas.0804105105 PMID: 18794521
46. Christoph S, Schlegel J, Alvarez-Calderon F, Kim YM, Brandao LN, et al. Bioluminescence imaging of leukemia cell lines in vitro and in mouse xenografts: effects of monoclonal and polyclonal cell populations on intensity and kinetics of photon emission. J Hematol Oncol. 2013; 6: 10. doi: 10.1186/1756-8722-6-10 PMID: 23343252
47. Inoue Y, Izawa K, Kiryu S, Kobayashi S, Tojo A, et al. Bioluminescent evaluation of the therapeutic effects of total body irradiation in a murine hematological malignancy model. Exp Hematol. 2008; 36: 1634-1641. doi: 10.1016/j.exphem.2008.08.004 PMID: 18951691
48. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood. 2009; 113: 6206-6214. doi: 10.1182/blood-2008-06-162123 PMID: 19050309
49. Rehemtulla A, Stegman LD, Cardozo SJ, Gupta S, Hall DE, et al. Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. Neoplasia. 2000; 2: 491-495. PMID: 11228541
50. Sweeney TJ, Mailander V, Tucker AA, Olomu AB, Zhang W, et al. Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci U S A. 1999; 96: 12044-12049. PMID: 10518573
51. Wang X, Rosol M, Ge S, Peterson D, McNamara G, et al. Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging. Blood. 2003; 102: 3478-3482. PMID: 12946998
52. McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013; 121: e34-42. doi: 10.1182/blood-2012-05-429555 PMID: 23243270
53. Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program. 2012; 2012: 35-42. doi: 10.1182/asheducation-2012.1.35 PMID: 23233558
54. Castro Alves C, Terziyska N, Grunert M, Gundisch S, Graubner U, et al. Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood. 2012; 119: 4224-4227. doi: 10.1182/blood-2011-08-370114 PMID: 22408264
55. Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005; 82: 389-396. PMID: 16533740
56. Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med. 2011; 17: 1086-1093. doi: 10.1038/nm.2415 PMID: 21873988
57. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011; 19: 138-152. doi: 10.1016/j.ccr.2010.12.012 PMID: 21251617
58. Distler E, Wolfel C, Kohler S, Nonn M, Kaus N, et al. Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice. Exp Hematol. 2008; 36: 451-463. doi: 10.1016/j.exphem.2007.12.011 PMID: 18261837
59. Goyama S, Schibler J, Cunningham L, Zhang Y, Rao Y, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013; 123: 3876-3888. doi: 10.1172/JCI68557 PMID: 23979164
60. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, et al. AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia. 2010; 24: 1785-1788. doi: 10.1038/leu.2010.158 PMID: 20686503